New Drug Approvals

Home » Malaria (Page 2)

Category Archives: Malaria

Advertisements
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 2,620,905 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,416 other followers

Follow New Drug Approvals on WordPress.com

Categories

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,416 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 year tenure till date Dec 2017, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 50 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 19 lakh plus views on New Drug Approvals Blog in 216 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

Verified Services

View Full Profile →

Categories

Flag Counter
Advertisements

WHO approves synthetic source of artemisinin


 

Artemesininby

Rachel Mundy

 13 May 2013

A genetically engineered source of the chemical required to make antimalarial drugs has received WHO approval, paving the way for improved access to affordable treatment against malaria in developing countries.

http://www.scidev.net/en/health/malaria/news/who-approves-synthetic-source-of-artemisinin.html?goback=%2Egmp_165490%2Egde_165490_member_240860517

Advertisements

Early malaria diagnosis-Raman spectroscopy identifies malarial infection by looking for parasite by-products


Early malaria diagnosis

13 May 2013

Scientists in Japan have developed a technique that could diagnose malaria just one day after infection

http://www.rsc.org/chemistryworld/2013/05/raman-spectroscopy-early-malaria-diagnosis-haem-hemozoin

ARTEMISININ AN ACE ANTIMALARIAL


Artemisinin

by on Jan 20, 2012

  • 956 views as on 12 may2013

Anthony Melvin Crasto presents Artemisinin, Glenmark scientist helping millions

amcrasto@gmail.com

http://www.slideshare.net/anthonycrasto64/anthony-melvin-crasto-presents-artemisinin-11174931

The quinine-containing bark of the Cinchona tree is probably the most valuable drug the Americas gave the world


The quinine-containing bark of the Cinchona tree is probably the most valuable drug the Americas gave the world

Read more  at chemistryviews

http://www.chemistryviews.org/details/ezine/4701281/From_Pharmacy_to_the_Pub_

_A_Bark_Conquers_the_World_Part_1.html

Cinchona or Quina is a genus of about 38 species in the family Rubiaceae, native to the tropical Andes forests of western South America. They are medicinal plants, known as sources for quinine and other compounds.

The name of the genus is due to Carolus “Carl” Linnaeus, who named the tree in 1742 after a Countess of Chinchón, the wife of a viceroy of Peru, who, in 1638, was introduced by native Quechua healers to the medicinal properties of cinchona bark. Stories of the medicinal properties of this bark, however, are perhaps noted in journals as far back as the 1560s–1570s.

It is the national tree of Ecuador and Peru.

Peru offers a branch of cinchona toScience (from a 17th-century engraving):Cinchona, the source of Peruvian bark, is an early remedy against malaria.

The medicinal properties of the cinchona tree were originally discovered by the Quechua peoples of Peru and Bolivia, and long cultivated by them as a muscle relaxant to halt shivering due to low temperatures. The Jesuit Brother Agostino Salumbrino (1561–1642), an apothecary by training and who lived in Lima, observed the Quechua using the quinine-containing bark of the cinchona tree for that purpose. While its effect in treating malaria (and hence malaria-induced shivering) was entirely unrelated to its effect in controlling shivering from cold, it was nevertheless the correct medicine for malaria. The use of the “fever tree” bark was introduced into European medicine by Jesuit missionaries (Jesuit’s bark). Jesuit Barnabé de Cobo (1582–1657), who explored Mexico and Peru, is credited with taking cinchona bark to Europe. He brought the bark from Lima to Spain, and afterwards to Rome and other parts of Italy, in 1632. AfterSpanish colonization of the Americas, the Jesuit missionaries were the first to bring the Jesuit’s bark cinchona compound to Europe in 1632. To maintain their monopoly on cinchona bark, Peru and surrounding countries began outlawing the export of cinchona seeds and saplings beginning in the early 19th century.

Meanwhile, also in the 19th century, the plant’s seeds and cuttings were smuggled out for new cultivation at cinchona plantations in colonial regions of tropical Asia, notably by the British to the British Raj and Ceylon (present day India and Sri Lanka), and by theDutch to Java in the Dutch East Indies (present day Indonesia).

As a medicinal herb, cinchona bark is also known as Jesuit’s bark or Peruvian bark. The bark is stripped from the tree, dried, and powdered for medicinal uses. The bark is medicinally active, containing a variety of alkaloids including the antimalarial compoundquinine and the antiarrhythmic quinidine. Currently, their use is largely superseded by more effective modern medicines.

quinine

 

 

cinchonine

 

PRECLINICAL- 4-quinolone prodrugs, pP4Q-414 , potential treatment of multi-drug resistant Plasmodium falciparum malaria


Medicines for Malaria Venture is investigating 4-quinolone prodrugs including pP4Q-414 (structure shown) and pP4Q-435, for the potential treatment of multi-drug resistant Plasmodium falciparum malaria.

In April 2013, data were presented at the 104th AACR Meeting in Washington DC. Of the compounds screened, pP4Q-414 and pP4Q-435 prodrug of P4Q-146 and P4Q-158 respectively, showed potent activity against P falciparum. In vivo, of the five mice evaluable, one mouse was cured with pP4Q-414 (at po 10 mg/kg) treatment and two of the five mice were cured with pP4Q-435 (at po 50 mg/kg) treatment

Launch of semi-synthetic artemisinin a milestone for malaria, synthetic biology


Apr 11th, 2013

Launch of semi-synthetic artemisinin a milestone for malaria, synthetic biology

(Nanowerk News) Twelve years after a breakthrough discovery in his University of California, Berkeley, laboratory, professor of chemical engineering Jay Keasling is seeing his dream come true.
On April 11, the pharmaceutical company Sanofi will launch the large-scale production of a partially synthetic version of artemisinin, a chemical critical to making today’s front-line antimalaria drug, based on Keasling’s discovery.read more at nanowerk

http://www.nanowerk.com/news2/biotech/newsid=29955.php

The “semi-synthetic” artemisinin is chemically modified to an active drug, such as artesunate, and combined in ACT with another antimalarial drug to lessen the chance that the malaria parasite will develop resistance to artemisinin. Sanofi plans to produce 35 tons of artemisinin in 2013 and, on average, 50 to 60 tons a year by 2014, which will translate to between 80 and 150 million ACT treatments.

Sweet wormwood was used in ancient Chinese therapy to treat various illnesses, including fevers typical of malaria. In the 1970s, Chinese scientists rediscovered it and identified its active ingredient, artemisinin, and artemisinin is now extracted from sweet wormwood grown commercially in China, Southeast Asia and Africa. The quality, supply and cost have been unpredictable and inconsistent, however. Keasling’s goal was to create a synthetic version with a stable and ideally lower price that could be produced in sufficient quantity to treat the 300-500 million cases of malaria that arise each year.

Sanofi and OneWorld Health, the not-for-profit drug development affiliate of the Program for Appropriate Technology in Health (PATH), have launched a commercial-scale production line for semisynthetic artemisinin, a move they say is “a pivotal milestone in the fight against malaria”.

Global demand for artemisinin is the most effective malaria treatment available but the existing botanical supply – which is derived from the sweet wormwood plant – is inconsistent. Therefore, Sanofi says that having “multiple sources of high-quality artemisinin will strengthen the artemisinin supply chain, contribute to a more stable price and ultimately ensure greater availability of treatment”.

The company notes that the production line at its facility in Garessio, Italy, will be able to produce enough artemisinin, using technology developed by US firm Amyris, for around 80-150 million artemisinin-based combination therapies by 2014.

%d bloggers like this: